ASH 2018 | JCAR017 for relapsed/refractory CLL
Thanks for your feedback, this will help us improve our content for you!
Tanya Siddiqi, MD, of the City of Hope, Duarte, CA., discusses the results of the TRANSCEND CLL-004 (NCT03331198) trial investigating the efficacy and safety of the anti-CD19 CAR T-cell product JCAR017 [(lisocabtagene maraleucel (liso-cel)] for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Siddiqi describes the positive response rates witnessed in the trial.
Get great new content delivered to your inboxSign up